Cuur Diagnostics

Vaginal Microbiota Panel

VAGINAL MICROBIOTA PANEL

CUUR DiagnosticsTM is dedicated to maintaining the largest data set of infectious disease targets available in the world.

The implications of diagnosing women’s health infections extend far beyond that of each patient – it can affect their partners and even their children. Particularly when it comes to infectious disease, it’s essential to get fast, reliable and actionable results.

The newly discovered female urinary microbiota has the potential to deepen our understanding of urinary tract health and disease, including common lower urinary tract conditions such as urinary incontinence and urinary tract infection. The female urinary microbiota possesses characteristics that differ between women affected by urgency urinary incontinence and matched, unaffected controls.

Traditional culture-based or microscopy-based methods for analysis of the vaginal microbiota can be time-consuming, overly subjective and inaccurate due to lack of sensitivity and specificity. CUUR Diagnostics’ molecular technology solution can detect microbes that are slow growing, difficult to grow or that fail to grow under traditional methods providing clear, precise and actionable categorization of microorganisms involved.

Helix DNA
TARGETS
[table “” not found /]

Infectious Disease Care

D I A G N O S T I C S

STATISTICALLY SPEAKING
  • Vulvovaginal candidiasis (VVC) affects about 75% of reproductive-aged women at least once during their lives, with about 5% of them suffering of recurrences.
  • Chlamydia trachomatis (CT) represents the most common bacterial STI worldwide, and new infections probably exceed 131 million per year